Region — US. Neutral scientific reference — not offered for sale here.
Set region
Vallydia
ExploreShopToolsJournalTrustSearch ⌕
Explore  /  AICAR (Acadesine)
Research reference — not for sale

AICAR (Acadesine)

F
lead outcome
Endurance / exercise performance (the…
grades vary by outcome ↓
Small molecule (non-peptide)⚠ WADA-banned
also called — AICAR · AICAr · Acadesine (its drug name) · AICA-riboside · 5-aminoimidazole-4-carboxamide ribonucleoside · (intracellular active form: ZMP). INCI: none
metabolicendurance / performance (exercise mimetic)fat oxidationinsulin sensitivity(cardioprotection, as Acadesine)

The original "exercise in a pill" — and the register's best doping-scandal story. This entry closes the exercise-mimetic triad and carries genuine intrigue. Three threads: (1) it's the compound behind the famous "44% more endurance in sedentary mice" headline that coined "exercise mimetic"; (2) that

In brief

AICAR (Acadesine) is a small-molecule AMPK activator — not a peptide — and the original "exercise in a pill." By entering cells and mimicking AMP (as ZMP), it switches on AMPK, the master energy sensor, triggering a metabolic shift toward fat oxidation, insulin-independent glucose uptake, mitochondrial biogenesis (PGC-1α) and autophagy. Its fame comes from Narkar et al. (Cell, 2008): sedentary mice given AICAR for 4 weeks ran ~44% longer with no training — the study that coined "exercise mimetic." That headline launched a genuine doping saga: WADA banned it in 2009, French authorities suspected it at the Tour de France, and a supply-network bust followed in 2012 — with the striking irony that the discoverer of its performance effect (Ronald Evans) also created the anti-doping test for it. Meanwhile it lived a double life as a legitimate cardiac-surgery drug candidate and the lab's #1 AMPK research tool — until a 2021 review showed many of its effects are AMPK-independent, complicating decades of interpretation. The honest bottom line: elegant, historically important biology; zero human endurance data; a banned, detectable substance in sport; and a mechanism messier than its "clean AMPK activator" reputation.

Legal standing, by region
European Union
Not FDA-approved (gray-market)

not an approved consumer drug; Acadesine did not reach general approval. Investigational / research chemical. Not a cosmetic.

⚠ WADA-prohibited in sportSport — WADA-prohibited since 2009 (S4 metabolic modulators), banned at all times, in and out of competition; detectable in blood/urine; serious sanctions. This is one of the register's most enforcement-relevant compounds in a sporting context.
Evidence, by outcome

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade
Endurance / exercise performance (the marketed use)
Landmark — but mouse-only; no human endurance trials; WADA-banned precisely for this
Narkar 2008 (Cell): sedentary mice +~44% running endurance, type-I fiber shift
F
Fat oxidation / metabolic / insulin sensitivity
Strong mechanistic/animal data; not established as a human therapeutic
Well-characterised: AMPK → ACC inactivation, GLUT4, PGC-1α (cells + animals)
F
Cardioprotection (Acadesine, cardiac surgery)
Real clinical study history — but did not achieve general approval; not a consumer indication
Legitimate clinical trials in cardiac-surgery ischemia
C
AMPK-activation (as a research tool)
BUT 2021 review: many effects AMPK-independent → interpret AICAR-only studies cautiously
Decades of use as the standard AMPK probe
B
Human safety (self-use)
Trials: transient uric-acid rise, mild lactic acidosis, possible hypoglycemia (insulin-independent glucose uptake); no organ-toxicity signal noted — but gray-market self-injection is unstudied, and it's banned/detectable in sport
Trial data at therapeutic doses

Identity a cell-permeable small molecule — a purine nucleoside — that acts as a pharmacological activator of AMPK (AMP-activated protein kinase), the cell's "master metabolic energy sensor." It is itself biologically inert until it enters cells (via adenosine transporters) and is phosphorylated to ZMP, an AMP-mimic that allosterically switches AMPK on. It has been the most widely used AMPK activator in laboratory research for decades — and, separately, a clinical drug candidate (Acadesine). ## Mechanism (as proposed) AICAR is a nucleoside that enters cells through adenosine transporters (ENT1/2, CNT2/3), where it's phosphorylated to ZMP — a molecule that mimics AMP. Rising "AMP-like" signal allosterically activates AMPK, the master sensor that cells use to detect low energy. Activated AMPK flips the metabolic switch from anabolic (storing) to catabolic (burning): it phosphorylates/inactivates ACC (↑fatty-acid oxidation), translocates GLUT4 (↑glucose uptake, insulin-independent), activates PGC-1α (↑mitochondrial biogenesis), and inhibits mTORC1 (↓protein synthesis, ↑autophagy) — collectively reproducing much of the muscle's response to endurance exercise. Elegant and foundational — but note the 2021 caveat that some AICAR actions bypass AMPK entirely.

Sources — 5 cited
01Narkar VA, et al. AMPK and PPARδ Agonists Are Exercise Mimetics. Cell. 2008;134:405-415 (the ~44% endurance / "exercise mimetic" paper; Evans lab, Salk).
02Visnjic D, et al. AICAr, a widely used AMPK activator with important AMPK-independent effects: a systematic review. Cells. 2021 (the AMPK-independence caveat).
03WADA Prohibited List (AICAR added 2009; S4 metabolic modulators); doping-control detection methodology for AICAR/GW501516 (Evans-derived methods).
04Acadesine cardiac-surgery clinical literature (myocardial protection/ischemia); Corton JM, et al. Eur J Biochem. 1995 (AICAR as AMPK activator).
05(No human endurance-efficacy trials; partner compound GW501516 dropped for carcinogenicity.)
Review status
Not yet reviewed

A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026 (status: foundational animal data, no human endurance trials, WADA-banned; watch AMPK-activator drug development — e.g. next-gen activators like O304 — rather than AICAR itself).

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds
SLU-PP-332 (ERR agonist / "exercise mimetic")F
Small molecule (non-peptide)
MOTS-cC
Peptide
5-Amino-1MQ (NNMT inhibitor)F
Small molecule (non-peptide)
Explore by goal
Metabolic
Vallydia

A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.

Region — United States
ExploreRegisterCategoriesTrust & COA
ShopCosmetic peptidesJournal
TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.

AICAR (Acadesine) — the original exercise-mimetic AMPK activator: the science, the Tour de France scandal, the caveats · Vallydia